Skip to content
Decision-ready map
• Teach the measurement chain: biology → optics → sensor → algorithm → decision
• Show how Hb, skin scattering, perfusion, hormones alter optical signatures
• Train students to report subgroup distributions, not only pooled means
• Connect NIH SABV + FDA expectations to study design and reporting
• Assess learning via decision-ready validation checklists
(1) What it is
Theme 5 is a teachable measurement-chain problem: biology → optical transport → sensor output → algorithm → decision. Biological sex can alter optical signatures through hemoglobin distributions (absorption), skin structure (scattering/path length), and perfusion dynamics (signal amplitude and variability). Because many clinical uses are threshold-driven, the most important lesson is how subgroup tail risk emerges even when average performance looks acceptable.
(2) Who it helps
This brief supports educators teaching biophotonics, biomedical engineering, physiology, and evidence literacy. It is suitable for undergraduate-to-postgraduate modules and for responsible innovation content.
(3) What evidence exists
You can anchor lessons in accessible primary studies. PPG work demonstrates sex-dependent waveform features relevant to wearable analytics (Dehghanojamahalleh & Kaya 2019). Large-cohort DRS inversions quantify absorption and scattering and report differences across sex, age, and BMI, showing that optical property ‘priors’ vary in real populations (Jonasson et al. 2023). Cutaneous microcirculation work combining DRS and laser Doppler shows sex differences in RBC tissue fraction and perfusion across rest and workload—ideal for teaching physiology-to-signal mapping (Samils et al. 2023). Time-resolved NIRS demonstrates sex differences in baseline oxygenated hemoglobin while optical properties are similar, emphasizing baseline interpretation (Asahara & Matsukawa 2023). Fluorescence spectroscopy shows sex-related differences in skin autofluorescence intensity (Morvová et al. 2018), and Raman serum spectroscopy illustrates how spectra embed multi-biomarker composition (Staritzbichler et al. 2021). At the policy interface, NIH’s SABV framework and FDA’s sex-specific device guidance provide real-world translation expectations for study design, analysis, and reporting.
(4) Translation barriers
Educational barriers include conflating sex with gender, treating optical outputs as ground truth, and ignoring device heterogeneity. Students also often focus on mean error and ignore tail-risk near thresholds. Finally, classroom datasets rarely include mediators (Hb, life stage), so educators need to explicitly teach ‘what to measure’ to interpret subgroup effects.
(5) Equity/safety checks
Teach respectful definitions and privacy-aware data handling. Emphasize mechanistic mediators (Hb, scattering, perfusion) rather than stereotypes. Include pregnancy explicitly as a high-impact life stage that is often underrepresented in validation. Frame equity as scientific rigor: disaggregation, transparency, and safe decision design.
(6) Decision questions
• Can learners map sex-linked variables onto the measurement chain and propose how each could alter the signal?
• Do assignments require disaggregated reporting and interpretation (including tail risk near thresholds)?
• Can students design a validation protocol aligned with NIH SABV and FDA expectations?
• Do learners distinguish sex from gender and handle consent/privacy considerations?
• Can they produce decision-ready checklists for a stakeholder (clinician, founder, payer)?
(7) Practical next steps
1) Teach the measurement chain and have students annotate where sex-linked biology enters the model.
2) Assign a ‘paper-to-checklist’ exercise: convert evidence into validation questions for a chosen stakeholder.
3) Run a procurement/regulatory role-play demanding sex-stratified evidence and safe-use guardrails.
4) Grade decision-ready artifacts (metrics, thresholds, mitigation plan) instead of summaries.
5) Include an ethics mini-module on definitions, consent, and minimal necessary data collection.
(8) References
Dehghanojamahalleh S, Kaya M. Sex-Related Differences in Photoplethysmography Signals Measured From Finger and Toe. IEEE J Transl Eng Health Med. 2019;7:1900607.
https://doi.org/10.1109/JTEHM.2019.2938506
Charlton PH, Pilt K, Kyriacou PA. Establishing best practices in photoplethysmography signal acquisition and processing. Physiol Meas. 2022;43(5):050301.
https://doi.org/10.1088/1361-6579/ac6cc4
Jonasson H, Fredriksson I, Bergstrand S, et al. Absorption and reduced scattering coefficients in epidermis and dermis from a Swedish cohort study. J Biomed Opt. 2023;28(11):115001.
https://doi.org/10.1117/1.JBO.28.11.115001
Samils L, Henricson J, Strömberg T, Fredriksson I, Iredahl F. Workload and sex effects in comprehensive assessment of cutaneous microcirculation. Microvasc Res. 2023;148:104547.
https://doi.org/10.1016/j.mvr.2023.104547
Asahara R, Matsukawa K. Prefrontal oxygenation is quantified with time-resolved NIRS: effect of sex on baseline oxygenation and response during exercise. Am J Physiol Regul Integr Comp Physiol. 2023;325:R31–R44.
https://doi.org/10.1152/ajpregu.00048.2023
Morvová M Jr, Jeczko P, Šikurová L. Gender differences in the fluorescence of human skin in young healthy adults. Skin Res Technol. 2018;24(4):599–605.
https://doi.org/10.1111/srt.12471
Hung C-H, Chou T-C, Hsu C-K, Tseng S-H. Broadband absorption and reduced scattering spectra of in-vivo skin using δ-P1 approximation. Biomed Opt Express. 2015;6(2):443–456.
https://doi.org/10.1364/BOE.6.000443
Staritzbichler R, Hunold P, Estrela-Lopis I, et al. Raman spectroscopy on blood serum samples of patients with end-stage liver disease. PLoS One. 2021;16(9):e0256045.
https://doi.org/10.1371/journal.pone.0256045
WHO. Guideline on haemoglobin cutoffs to define anaemia in individuals and populations. 2024.
https://www.who.int/publications/i/item/9789240088542
NIH Office of Research on Women’s Health. Sex as a Biological Variable (SABV).
https://orwh.od.nih.gov/sex-as-biological-variable
FDA. Evaluation of Sex-Specific Data in Medical Device Clinical Studies (final guidance). March 2025.
https://www.fda.gov/regulatory-information/search-fda-guidance-documents/evaluation-sex-specific-data-medical-device-clinical-studies-guidance-industry-and-food-and-drug